IOVANCE BIOTHERAPEUTICS Files 8-K on Financials
Ticker: IOVA · Form: 8-K · Filed: Feb 27, 2025 · CIK: 1425205
| Field | Detail |
|---|---|
| Company | Iovance Biotherapeutics, Inc. (IOVA) |
| Form Type | 8-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: IOVA
TL;DR
IOVA filed an 8-K on Feb 27, 2025, covering financial results and operations.
AI Summary
On February 27, 2025, IOVANCE BIOTHERAPEUTICS, INC. filed an 8-K report detailing results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Lion Biotechnologies, Inc. until October 15, 2013.
Why It Matters
This 8-K filing provides crucial updates on IOVANCE BIOTHERAPEUTICS' financial health and operational results, which are essential for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for financial reporting and does not indicate any immediate or significant new risks.
Key Players & Entities
- IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
- February 27, 2025 (date) — Date of Report
- Lion Biotechnologies, Inc. (company) — Former Company Name
- October 15, 2013 (date) — Date of Name Change
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this report filed with the SEC?
The report was filed on February 27, 2025.
What is the company's Central Index Key (CIK)?
The company's CIK is 0001425205.
What was IOVANCE BIOTHERAPEUTICS, INC. previously named?
The company was formerly known as Lion Biotechnologies, Inc.
What is the company's state of incorporation?
The company is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 27, 2025 regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).